-
Rheumatology: alkaline calcium phosphate crystals induce the expression of extracellular matrix remodeling enzymes in tendons
Time of Update: 2022-08-15
Real-time PCR was used to determine changes in the expression of tendon-related genes and extracellular matrix remodeling enzymes (metalloproteinases, MMPs; disintegrins and metalloproteinases, ADAMTS; tissue inhibitors of metalloproteinases, TIMPs) .
-
In 2021, revenue and net profit will decline. Where is Hengrui's hope
Time of Update: 2022-06-05
The company said that in the future, it will increase investment in research and development, deepen the internationalization strategy, and promote the overseas listing and sales of the company's key generic drug varieties and innovative drug products .
-
Pharmaceutical companies have accelerated the process of commercialization and enhanced the ability of "hematopoietic
Time of Update: 2022-04-20
The announcement also pointed out that at the same time as the new drug was launched, TOT BIOPHARM and domestic pharmaceutical companies carried out strategic cooperation in market promotion, promoted the process of product commercialization, and improved the availability of drugs .
-
Sino-US expert summit dialogue, comprehensive exchange of frontier topics in diagnosis and treatment of tardive dyskinesia
Time of Update: 2022-02-22
*Only for medical professionals to read and refer to "Concentrate", discuss the diagnosis and treatment of tardive dyskinesia! Tardive Dyskinesia (TD) is a special and persistent extrapyramidal respo
-
Annual review of new drugs and programs approved by the FDA for hematological malignancies in 2021
Time of Update: 2022-01-26
July 16, 2021 FDA approves selective Rho-related coiled-coil kinase 2 (ROCK2) inhibitor belumosudil for the treatment of chronic graft-versus-host disease (cGVHD) in adults and children ≥12 years of age who have failed ≥2 previous lines of systemic therapy The approval was based on a randomized, open-label, multicenter study (KD025-213 study) .
-
For these patients at high risk of AS structural damage, the long-term benefits of treatment are the key
Time of Update: 2021-04-23
A number of studies have explored the predictive factors of long-term structural damage in AS, which may bring new inspiration for clinical treatment.
A number of studies have explored the predictive factors of long-term structural damage in AS, which may bring new inspiration for clinical treatment.
-
Johnson and Johnson Amivantamab Dual Anti-Domestic Start-Up Phase III Clinical has submitted BLA to the FDA
Time of Update: 2020-12-22
addition, according to the Insight database, Johnson and Johnson registered six Amivantamab clinical trials at ClinicalTrials.gov, including two Phase III clinical trials, and in addition to taking drugs with Lazertinib, Johnson and Johnson explored Amivantamab's joint treatment with Capra/Pemite to treat NSCLC patients inserted by EGFR 20 exons.
-
The second one! It's clear that "Kaglie Net Film" has been approved for sale
Time of Update: 2020-10-20
On September 28th, Zhengda Tianqing Class 4 generic drug Kaglie Net Tablet was approved for listing by NMPA, becoming the second domestic generic drug market after Haussen Pharmaceuticals.
-
Esperion publishes results of Phase 3 clinical trial on long-term safety of the new drug bempedoic acid
Time of Update: 2020-06-10
recently, Esperion (http:// announced that it is developing the results of the long-term trial (http:// for long-term safety the new drug (http:// ) bempedoic acid About Bempedoic acid Bem
-
Methadone insomnia therapy is approved, and Novartis met inhibitor is qualified for priority review
Time of Update: 2020-02-17
MSD company announced that FDA approved it to update the label information of belsomra (suvorexant), reflecting its clinical data in the treatment of insomnia symptoms in patients with mild to moderat
-
Heavyweight update! In the next three years, Novartis R & D pipeline will submit 60 new drug applications
Time of Update: 2018-11-07
Novartis recently demonstrated its industry-leading R & D pipeline assets at the R & D and investor Update Conference in London, UK, and promised to submit no less than 60 important regulatory applica
-
List of important clinical trials in China in 2018 (3
Time of Update: 2018-03-15
Source: Sina Pharma 2018-03-15 CFDA issued relevant policies on encouraging innovation and reform of clinical trial management of pharmaceutical and medical devices, which will further promote the dev
-
Development and patent progress of CDK4 / 6 inhibitors in more than 20 domestic companies
Time of Update: 2017-12-02
Two days ago, an article entitled "two nature confirmed that this kind of heavy-duty anticancer drugs can make cancer immunotherapy change" cattle ", wrote that in August this year, a study on nature
-
A new one-off cure for influenza
Time of Update: 2017-07-28
[product information of China Pharmaceutical network] s-033188, developed by yanye pharmaceutical company of Japan, is a 5-cap-dependent endonuclease inhibitor It is a new clinical drug in research th
-
The market terminal of cardiovascular drugs in China will break through 150 billion! New drugs continue to drive growth
Time of Update: 2015-12-09
Source: with the rapid development of global economy and the continuous change of life style, the spectrum of human diseases has changed significantly Cardiovascular disease has become the number one
